Alcohol Use DisorderNCT07525258
Implementation Facilitation Pilot for Alcohol Use Disorder (AUD) in Alcohol-associated Liver Disease (ALD)
A study testing Implementation Intervention in people with Alcohol Use Disorder and Alcohol-associated Liver Disease, run by Yale University at 1 site in United States.
Trial summary
The goal of this project is to improve provision of integrated medications for alcohol use disorder (MAUD) with brief counseling for patients with alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) in hepatology clinics. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Alcohol Use Disorder, Alcohol-associated Liver Disease
- What is being tested?
- Implementation Intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteUnited States
- Study dates
- 5 Apr 2026to Apr 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Must provide care for patients with liver disease at a hepatology clinical location within the Yale School of Medicine and YNHH medical system.
Who cannot join
- Providers who do not treat patients with chronic liver disease and alcohol-associated liver disease.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Yale School of Medicine/Yale-New Haven Health
New Haven, Connecticut, 06520
About this study
Official title: Feasibility and Acceptability of a Novel Implementation Intervention to Promote Alcohol Use Disorder Treatment in Hepatology Clinics
The goal of this project is to improve provision of integrated medications for alcohol use disorder (MAUD) with brief counseling for patients with alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) in hepatology clinics. There are many benefits of AUD treatment among patients with AUD and ALD such as reduction in liver-related complications and hepatology clinicians providing this care in an integrated fashion can improve access and uptake.
- Being tested
- Implementation Intervention
- Keywords
- Clinicians, Medications for Alcohol Use Disorder
- Medical subject headings
- Alcoholism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Implementation InterventionBehavioural
A multipronged intervention including hepatology clinician education, patient education, clinical decision support, and clinician audit and feedback which will be adapted and tested.
| Study group | Role | What they receive |
|---|---|---|
| Hepatology Clinicians | Experimental | Clinician participants will participate in a multipronged intervention including hepatology clinician education, patient education, clinical decision support, and clinician audit and feedback which will be adapted and tested. Participants will attend two approximately 60-minute-long educational sessions in which key points related to AUD treatment based on the HPCR resource and implementation facilitation intervention will be reviewed. Receives: Behavioral: Implementation Intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility
Percentage of clinicians enrolled out of all recruited
Measured: 12 months
Secondary outcomes (1)
Acceptability
Percentage of clinicians that attend the educational workshops and utilize implementation tools.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Apr 2026
- Study start5 Apr 2026
- Primary completionApr 2029 (estimated)
- Study completionApr 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alcohol Use DisorderStudies of the same condition, open and under way.
- More trials run by Yale UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Hepatology clinicians including attending physicians, trainees, and advanced practice providers will be invited to participate in an implementation facilitation intervention to improve AUD treatment in hepatology clinics. The interventions will include education, patient materials, clinical decision support tools and coaching/feedback.
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Yale University
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Responsible party
- Sponsor
- Investigators
- Lamia Haque, Principal investigator, Yale University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07525258
- Sponsor's protocol ID
- 2000038799
- Other IDs
- 1K23AA031334-01
- Status last verified
- May 2026
- First submitted
- 6 Apr 2026
- Last updated
- 7 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility and Acceptability of a Novel Implementation Intervention to Promote Alcohol Use Disorder Treatment in Hepatology Clinics
- ClinicalTrials.gov ID
- NCT07525258
- Acronym / sponsor ID
- 2000038799
- Keywords
- Clinicians, Medications for Alcohol Use Disorder
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Yale UniversityUniversity, hospital or other
- Collaborators
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Study start
- 5 Apr 2026 (actual)
- Primary completion
- Apr 2029 (estimated)
- Study completion
- Apr 2029 (estimated)
- First posted
- 13 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this project is to improve provision of integrated medications for alcohol use disorder (MAUD) with brief counseling for patients with alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) in hepatology clinics. There are many benefits of AUD treatment among patients with AUD and ALD such as reduction in liver-related complications and hepatology clinicians providing this care in an integrated fashion can improve access and uptake.
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Hepatology clinicians including attending physicians, trainees, and advanced practice providers will be invited to participate in an implementation facilitation intervention to improve AUD treatment in hepatology clinics. The interventions will include education, patient materials, clinical decision support tools and coaching/feedback.
| Arm | Type | Receives |
|---|---|---|
| Hepatology Clinicians | Experimental | Behavioral: Implementation InterventionClinician participants will participate in a multipronged intervention including hepatology clinician education, patient education, clinical decision support, and clinician audit and feedback which will be adapted and tested. Participants will attend two approximately 60-minute-long educational sessions in which key points related to AUD treatment based on the HPCR resource and implementation facilitation intervention will be reviewed. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Must provide care for patients with liver disease at a hepatology clinical location within the Yale School of Medicine and YNHH medical system.
Key exclusion criteria (1 listed)
- Providers who do not treat patients with chronic liver disease and alcohol-associated liver disease.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Implementation InterventionA multipronged intervention including hepatology clinician education, patient education, clinical decision support, and clinician audit and feedback which will be adapted and tested. | Behavioural | Hepatology Clinicians |
Primary outcome
Feasibility
Time frame: 12 months
Percentage of clinicians enrolled out of all recruited
1 secondary outcome
Acceptability
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 May 2026.
- Individual participant dataSharing planned: No
Related trials for Alcohol Use Disorder
Recruiting
Tdcs And cogNitive traininG cOmbined for AUD (TANGO)
Alcohol Use Disorder, Addiction
Recruiting
Developing a Novel Human Laboratory Paradigm for AUD Medication Screening
Alcohol Use Disorder
RecruitingPhase 1
Environment and Alcohol: A Pilot Study
Alcohol Use Disorder
RecruitingPhase 2
Phase 2 Study of Apremilast in Women and Men With Alcohol Use Disorder
Alcohol Use Disorder
Not yet recruitingPhase 1/2
Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients
Alcohol Withdrawal, Alcohol Abstinence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Lamia Haque principal investigator
Yale University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Implementation Intervention in people with Alcohol Use Disorder and Alcohol-associated Liver Disease, run by Yale University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 7 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lamia Haque, MD MPH ((203) 777-0304, lamia.haque@yale.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 May 2026; AzTrials last refreshed its copy on 31 Oct 2026.